TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Serum Iron Levels From Baseline to 90 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to recurrence of a new acute bipolar episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experiences in Close Relationships - Revised questionnaire (ECR-r)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organisation Disability Assessment Schedule 2.0 (WHODAS 2.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in adult height (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total cumulative morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neurodevelopment Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Spontaneous Bowel Movements Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Signal Change in Right Caudate Nucleus in Men
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in Right Caudate Nucleus in Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in Left Insula in Men
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in Left Insula in Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in Left Caudate Nucleus in Men and Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Anti-drug Antibody (ADA)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life Using Chronic Respiratory Disease Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heart rate on-kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative recurrent laryngeal nerve palsy
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative hypocalcemia
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of oral infections
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the platelet activation ratio, %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in neutrophils MPO content, MFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the neutrophils with adherent platelets, %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the neutrophils with internalized platelets, %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major Molecular Response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Auditory memory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-invasive 1H Magnetic Resonance Spectroscopy of vastus lateralis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of lymph node metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Number of episodes of cough/wheeze/asthma/bronchitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Insulin Basal Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Area Under the Curve (AUC) of Plasma Insulin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Basal Endogenous Glucose Production (EGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in prolonged menstrual bleeding condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Satisfaction of Space on Resident Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Family Interactions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Conversion Rate of CE (From Positive to Negative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pre-operative pinch and grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-Reported Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean % Sessions Attended as Scheduled
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of follow-up visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Achieving ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hand Grip Strength Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Dexterity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient knowledge and adherence to follow-up care recommendations and health behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects achieving total testosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MLA measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroconversion proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean antibody titers (TGM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MRD status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of vaginal health index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline level of triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline level of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chemotherapy-induced Peripheral Neuropathy Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the blood glucose curve (AUC 0-240)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: agreement of systolic central blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: agreement of diastolic central blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: nocturnal fluid shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharyngeal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relief of nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of PONV in the 24 hours following end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuron specific enolase (NSE) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak rise of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful usage of the app
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnoses With Elevated Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recognition of anatomic cerebral structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Intraoperative Time with Cardiac Index ≥ 2.2 l/Min/m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Total Kidney Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: remifentanil total dose in microgram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted analgesic dose after anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Recurrent Colon Cancer
Endpoint domain: Mortality/survival
Primary endpoint: BNP levels following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Troponin levels following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with adverse cardiac outcomes following surgery
Endpoint domain: Adverse events/effects
Primary endpoint: changes in sarcopenia-related knowledge and awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscular Activity of Erector Spinae Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscular Activity of Biceps Femoris Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Posture (Thoracic Kyphosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Posture (Lumbar Lordosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Posture (Trunk Flexion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of Each Treatment Arm With ≥50% Reduction in Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Baseline fecal calprotectin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hrHPV DNA status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dentinal hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Vitamin B12 delivered into the systemic circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in symptoms of anxiety based on SCARED
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms of anxiety based on PARS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Angiogenic factors in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VO2 Peak - Cardiorespiratory Fitness Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DEXA - Body Composition Overall Body Fat % Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic Blood Chemistries - HbA1c Level Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak plasma concentration (Cmax) of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Intraocular Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year risk of non-fatal acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 10-year risk of coronary heart disease death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in POP-Q points Aa and Ba
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in POP-Q point C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No unexpected serious adverse device related events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum Potassium from Part A Baseline to Part A Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Serum Potassium from Part B Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Headache score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Force generating ability of quadriceps femoris and triceps surae (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voluntary muscle activation during a Maximal Volitional Isometric Contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle cross-sectional area of quadriceps femoris and triceps surae (via MRI with fat suppression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the number of Tumor Infiltrating Lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Levels of NfL (Neurofilament Light) in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Number of CD19+ B Cells in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Number of CD3+ T-Cells in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of surgical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Profile of Mood States (POMS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rey Auditory Verbal Learning Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Short-Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Days Between Referral and Start of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Community-acquired infections
Endpoint domain: Adverse events/effects
Primary endpoint: Development of second infections
Endpoint domain: Adverse events/effects
Primary endpoint: ICU care, organ failure, death, and disability
Endpoint domain: Mortality/survival
Primary endpoint: Management of complications of cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri and post-liver transplant outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional variations in outcomes
Endpoint domain: Resource use
Primary endpoint: Weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in NIH Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in serotonergic transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in pulmonary aeration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma and serum concentration of tamoxifen and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoxifen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lung Cancer Incidence
Endpoint domain: Mortality/survival
Primary endpoint: 10 Meters Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic visual acuity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without treatment-related serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients without significant drug intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Diagnosed With Fetal Macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-weeks progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: percentage of neonates requiring mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduction of muscle fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: improvement of respiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: improvement of functional fitness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With ACR 30 Response Who Did Not Experience a Flare of Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decayed, missing, and filled tooth surfaces (dmfs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of rapid interphase apoptosis in CLL cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Normalized Brain Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in Creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of parenting comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vascular Function (% Flow Mediated Vasodilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Control of type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Family Economic Strain
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in demand elasticity for preferred flavored filtered cigars
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in demand elasticity for preferred unflavored filtered cigars
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in cross price elasticity for filtered cigars and cigarettes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Genetic abnormalities associated with Early Onset Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric measurements on non-injured hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric measurements on injured hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1C at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with One or More Drug-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: CD4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in management plan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disease stabilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumour marker response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in neural activation on fMRI during driving simulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dopamine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline Fatty mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline Muscular Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes